Plain-English translation of NCT06969170 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing psilocybin oral solution — a 3 mg dose given by mouth — to see if it can safely help adults with generalized anxiety disorder (GAD), a condition marked by persistent, difficult-to-control worry. The study will measure how well the medication works, how safe it is, and how people tolerate it over several weeks of treatment.
Current anxiety treatments don't work well for everyone, and some people struggle with side effects or dependency. This research explores whether this medication might offer a new option for people whose anxiety hasn't improved enough with existing treatments.
You likely qualify if…
You likely don't qualify if…
The study lasts about 10 weeks total. First, you'll have a screening visit with medical tests and an anxiety assessment. Then you'll attend four weekly clinic visits over a month while taking the medication, with phone or email check-ins between visits. If your anxiety improves enough, you'll be randomly assigned to either continue the medication or switch to a placebo (inactive pill) for another 4 weeks, with similar visits and assessments. Throughout, you'll complete safety checks, answer questions about your anxiety and mood, and possibly have cognitive tests and brain wave recordings (EEG).
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Canada